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Title: Designing a Good Manufacturing Practices (GMP) Certified Manufacturing Unit for 
Halal Products in Gambang 
 
ABSTRACT 
An industry is a most important aspect in order to increase the economic status. Industry 
can also define as a basic category of business activity. Therefore, it is a need for Gambang 
area to have one industry based on HALAL product due to development of population. This 
paper is written out to design a Good Manufacturing Practices (GMP) certified 
manufacturing unit for halal products in Gambang. For pharmaceutical manufacturing unit, 
there are some requirements for complimentary medicines. They are quality management, 
personnel, premises & equipment, documentation, production, quality control, contract 
manufacture & analysis, complaints & recall and self inspection. The GMP scheme 
contains requirements and conditions for the safety of the manufacturing unit besides 
ensure the quality of the product. A standard GMP manufacturing unit has many benefits. 
Firstly, the GMP manufacturing unit can supply medical needed in a very large quantity. 
Secondly, the standardize from GMP regulation will provide a quality product that will 
ensure the health of people. Third, there will be a lot of job to be fulfilled by people in 
order to reduce unemployment problems in Malaysia. This GMP manufacturing unit can be 
done by two methods. First is by doing research and second is by doing industrial visit to 
get real surrounding of an industry. This research is very suitable to be done in Malaysia 
based on demanding on pharmaceutical needed. In order to reduce our dependence on other 
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country for supplying the medical needed, we should have ours. Hence, a GMP 
manufacturing unit is the most suitable to accommodate out medical needed.  
 
TABLE OF CONTENT 
 
BIL ORGANISATION PAGE 
1 ABSTRACT 1 
2 CHAPTER ONE - INTRODUCTION 4 
 1.1 Background Of Study 4 
 1.2 Statement Of Problems 5 
 1.3 Research Objectives 6 
 1.4 Expected Outcomes 6 
 1.5 Significant of Proposed Study 6 
 1.6 Conclusion 7 
3 CHAPTER TWO – LITERATURE REVIEW 8 
 2.1 Introduction 8 
 2.2 Good Manufacturing Practices 11 
 2.3 Monoclonal Antibodies (MABs) 23 
 2.4 Technological Progresses in Monoclonal Antibody 
Production Systems 
29 
4 CHAPTER THREE - METHODOLOGY 32 
3 
 
 
 
 3.1 Introduction 32 
 3.2 Design 32 
 3.3 Methodology 33 
 3.4 Conclusion 36 
5 CHAPTER 4 – RESULT AND DISCUSSION 37 
 4.1 Introduction 37 
 REFERENCES 40 
 APPENDIXES 42 
 
 
4 
 
 
 
 
 
 
CHAPTER ONE 
 
 
 
INTRODUCTION 
 
 
Title: Designing a Good Manufacturing Practices (GMP) Certified Manufacturing Unit for 
Halal Products in Gambang 
 
1.1     Background of study 
 
GMP stands for Good Manufacturing Practices and refers to the standards set by the United 
States Food and Drug Administration, FDA. Sometimes it also referred to as ‗cGMP‘. The 
‗c‘ stands for ‗current‘. GMP can be divided into four parts. They are Personnel, Premises, 
Equipment and Sanitation &Hygiene. This study of GMP manufacturing unit is started by 
investigation on pharmaceutical needed. Based on population in Gambang, Pahang, most of 
them are Muslim and need pharmaceutical products. That‘s why this GMP manufacturing 
unit will be designed based on HALAL gel capsules.  
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 Basically, GMP manufacturing unit is an overall regulation for all kind of 
industries. In this research, researcher only takes one part on manufacturing unit. 
Meanwhile, for HALAL products are the main production of the project. 
1.2     Statement of Problems 
 
‗If you look at the human condition today, not everyone is well fed, has access to good 
medical care, or the physical basics that provide for a healthy and a happy life.‘(Ralph 
Merkle). This situation shows that everyone in this world did not have enough medical 
care. This problem not just happens in Gambang Pahang. Actually, most developed country 
has to face the pharmaceutical crisis in order to ensure the wellness of the ecosystem.  As 
one of living place among Universiti Malaysia Pahang students, this student and staff are 
facing this problem. 
  
 Based on the observation that researcher has made the pharmaceutical needed is 
most important to guarantee healthier life among students and staff.  Furthermore, 
Universiti Malaysia Pahang only has one small clinic protect almost three thousand 
students and staff. Eventually, there are no places that can supply pharmaceutical needed in 
Gambang area. Since this happen, the problem might become worst. Hence, this paper is 
discussed about the designing of one manufacturing unit to produce HALAL products 
which follows GMP procedures in order to find an effective solution for this recent 
problem. 
6 
 
 
 
1.2.1 Research Objective 
 
The objective of this research paper area follows: 
1.3.1 To design a manufacturing unit of HALAL products in Gambang area which 
follow Good Manufacturing Practices (GMP) regulations.   
 
 
1.3 Scope of Study 
 
The scope of this study is to design a manufacturing unit that will produce pharmaceutical 
products. Basically, the method that will be used for designing a manufacturing unit will be 
divided into two parts. First is by doing research and literature review. Second task is by 
investigating the real manufacturing unit especially in Malaysia.  
 
 
1.4 Expected Outcomes 
 
This research is conducted in order to provide a HALAL pharmaceutical manufacturing 
unit in Gambang area. Besides that, this research will increase the economy development 
due to job opportunities for all citizens.  
 
 
1.5 Significant of Proposed Study 
 
A standard GMP manufacturing unit has many benefits. Firstly, the GMP manufacturing 
unit can supply medical needed in a very large quantity. Secondly, the standardize from 
GMP regulation will provide a quality product that will ensure the health of people. Third, 
there will be a lot of job to be fulfilled by people in order to reduce unemployment 
problems in Malaysia. Forth, GMP manufacturing unit will increase the stability of 
economic. 
7 
 
 
 
 
1.6 Conclusion  
 
This research is very suitable to be done in Malaysia based on demanding on 
pharmaceutical needed. In order to reduce our dependence on other country for supplying 
the medical needed, we should have ours. Hence, a GMP manufacturing unit is the most 
suitable to accommodate out medical needed.  
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CHAPTER 2 
 
 
 
LITERATURE REVIEW 
 
 
2.1      INTRODUCTION 
 
GMP is an efficient and effective way of accomplishing a task based on repeatable proven 
procedures. For pharmaceutical manufacturing unit, there are some requirements for 
complimentary medicines. They are quality management, personnel, premises & 
equipment, documentation, production, quality control, contract manufacture & analysis, 
complaints & recall and self inspection. The GMP scheme contains requirements and 
conditions for the safety of the manufacturing unit besides ensure the quality of the product. 
In the last decades, monoclonal antibodies (mAbs) have become increasingly important in 
terms of medical research, diagnosis, and therapy. They constitute more than 30% of total 
biopharmaceutical production (Rodrigues M. E et al., 2009). Georges Kohler and Cesar 
Milstein was the first people who produce the monoclonal antibodies in 1975. Most 
antibodies used in cancer diagnosis and therapy are derived from the IgG isotype. An IgG 
isotype antibody consists of two antigen-binding fragments (Fabs), which are connected via 
a flexible (the hinge) to a constant (Fc) region (Binyamin L, 2006). Now people can get 
another new technology in pharmaceutical field which is much better in curing the diseases. 
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Table 1 : Monoclonal Antibodies Approved for Clinical Application Until 2009, 
(Rodrigues M. E et al., 2009). 
 
Product Company Clinical Indication Approval 
ORTHOCLONE Ortho Biotech Acute kidney transplant rejection  1986 
OKT3
®
  Heart transplant rejection, liver 
transplantation 
1993 
REOPRO
® 
Centocor/Eli Lilly Percutaneous transluminal coronary 
angioplasty 
1994 
PANOREX
®
 Centocor/GlaxoSmi
thKline 
Colon cancers 1995 
ZENAPAX
®
 F. Hoffmann-La 
Roche 
Acute kidney transplant rejection 1997 
MABTHERA
®
/
RITUXAN
®
 
Biogen 
IDEC/Genzyme/F. 
Hoffmann-La 
Roche 
Follicular CD20 positive non-Hodgkin‘s 
B-cell lymphoma (NHL), non-Hodgkin‘s 
B-cell lymphoma (NHL) 
1997 
  Rheumatoid arthritis (RA) 2006 
SIMULECT
®
 Novartis Renal transplant rejection 1998 
SYNAGIS
®
 Abbott/MedImmun
e 
Respiratory Syncytial virus Disease 1998 
HERCEPTIN
®
 F. Hoffmann-La 
Roche/Genentech 
Metastatic breast cancers overexpressing 
ERBB2 
1998 
REMICADE
®
 Centocor Crohn‘s disease 1998 
  Ankylosing spondylitis, psoriatic arthritis, 
ulcerative colitis 
1999 
  Rheumatoid arthritis (RA) 2001 
MYLOTARG
®
 Wyeth Acute myeloid leukemia 2000 
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CAMPATH
® 
/ 
MABCAMPAT
H
®
 
Berlex / Genzyme / 
Millennium 
B cell chronic lymphocytic leukemia 2001 
HUMIRA
® 
/ 
TRUDEXA
®
 
Abbott Psoriatic and rheumatoid arthritis 2002 
ZEVALIN
®
 Biogen IDEC / 
Schering AG 
Non-Hodgkin‘s B-cell lymphoma 2002 
RAPTIVA
®
 Genentech / Merck 
Serono 
International / 
Xoma 
Psoriasis 2003 
XOLAIR
®
 Genentech / 
Novartis / Tanox 
Allergic asthma, severe persistent asthma 2003 
BEXXAR
®
 GlaxoSmithKline / 
Corixa 
Follicular CD20 positive non-Hodgkin‘s 2003 
  B-cell lymphoma (NHL) 2004 
AVASTIN
®
 Genentech Metastatic colorectal cancers, metastatic 
non-small-cell lung cancers 
2004 
ERBITUX
®
 Merek & Co / 
ImClone 
Metastatic colorectal cancers 2004 
TYSABRI
®
 Biogen IDEC / Elan Multiple sclerosis 2004 
THERACIM
®
 YM BioSciences Glioma cancers 2004 
VECTIBIX
TM
 Amgen Colorectal cancers 2006 
LUCENTIS
®
 Genentech / 
Novartis 
Neovascular age-related macular 
degeneration 
2006 
SOLIRIS 
TM 
Alexon Paroxysmal nocturnal hemoglobinuria 
(PNH) 
2007 
CIMZIA 
®
 Celltech, UCB Crohn‘s disease 2008 
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2.2       GOOD MANUFACTURING PRACTICES 
 
GMP manufacturing unit was the only manufacturing unit that follow standardize of GMP 
regulations. Therefore, the production of medical need from this GMP manufacturing unit 
will be ensuring in their quality and safety. Good Manufacturing Practices are standard 
guidelines set out by the FDA to ensure drug development is carried out in safe and quality 
processes, to avoid contamination and ensure repeatability. Here, the medical supply will 
be less contaminated in order to people supplement. 
 
According to Dias M.A.C et al. (2012), the implementation of GMP took place with the 
creation of a multidisciplinary team and it was carried out in four steps: diagnosis, report of 
the diagnosis and road map, corrective measures and follow-up of GMP implementation. 
The research in based on the implementation of good manufacturing practices in a small 
processing unity of mozzarella cheese in Brazil. GMP implementation was done in order to 
avoid or reduce the contamination of the products. General measures to be implemented by 
food industry accomplish with GMP as described by Codex Alimentarius include: hygiene 
in the primary production, hygiene design of equipment and facilities, control of operations, 
maintenance and sanitation practices, personal hygiene, transportation, product information 
and consumer awareness and training. The implementation of GMPs is a continuous 
process based on the management concepts of the PDCA cycle (plan, do, check and action). 
 
According to Beaumont N. et al (2005) who had made a research on Best Practice in 
Australian Manufacturing sites has review that best practices can be divided into some 
components. They are continuous, simultaneous improvement in cost, quality and delivery, 
closer link with supplier and customer‘s effective use of technology for strategic advantage, 
flatter organizational structures, greater flexibility and preparedness to adopt structures and 
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processes to changed circumstances, human resource policies promoting continuous 
learning, teamwork, participation and flexibility and comparison of performance with 
similar firms. There are three aspects of Best Practices: 
 
1. Operational Best Practices: Optimize operations on the factory floor. The objectives 
are usually tangible and include direct cost minimization, quality and on-time 
delivery. 
2. Internal Best Practices: Optimizes the manufacturer‘s structure, staffing, systems 
and culture so that manufacturing strategy is optimally expressed. If, for example, 
customers services is emphasized, customers will be able to order through web 
pages, these orders will be made available to factory schedulers instantly, there will 
be sophisticated scheduling and order tracking systems: and flexible manufacturing 
systems. 
3. External Best Practices: (a) Optimizes relations with external parties, especially 
customers and suppliers. (b) Obtains required resources (e.g. raw materials and 
labour) on the best possible terms and conditions. (c) Sells finished goods on the 
best possible terms and conditions. 
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Table 2: Component of manufacturing Best Practices (Beaumont N. 2005) 
 
Element Components 
Manufacturing Strategy Planning, manufacturing structure, factory 
operations. 
Manufacturing Practice Leadership, management of people, 
customer focus, quality of process and 
product, benchmarking, technology. 
Manufacturing Outcomes Cost, quality, flexibility. Timelines, 
innovation. Barriers, teams, 
competitiveness. 
Business Performance Sales, exports, employment, market share, 
cashflow. 
 
According to Santana N.G, (2009) which have some research about good manufacturing 
practices in public school catering in Brazil. The aim for the investigation was to evaluate 
the food safety of the services used to prepare the free meals in Salvador, Brazil and to 
adopt good manufacturing practices (GMP) in order to assure a safe supply of food for 
students. It concludes that it is necessary to introduce GMP in these facilities in order to 
ensure safe meals for students. For adoption of good manufacturing practices, it was 
divided into four parts. 
 
1. Educational training 
Food safety, hygiene and good manufacturing practices (GMP) were introduced. 
Discussion about the major problems in the school meals preparation areas and suggestions 
for correction and improvement were prompted. Then, the food handler‘s behavior at the 
workplace was monitored for one week. 
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2. Cleaning and Sanitizing 
These steps were monitored by visually inspecting for organic material after cleaning and 
sanitizing utensils. 
 
3. Personal hygiene 
Sanitation supplies including disposable gloves, disposable masks and antiseptic agents 
were obtained and introduced into the cafeteria. 
 
4. Monitoring time and temperature 
The time and temperature were monitored by inserting a thermometer into foods during all 
stages of the preparation and distribution. Measuring started as soon as the last food 
transformation was completed. 
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Figure 1: Flow Diagram used for GMP investigation. (Santana N.G, 2009) 
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Table 3 : The elements of a GMP system which apply to the manufacture of paper and 
board for food contact 
 
Component of the GMP System Need Comments 
General   
ISO 9001 or equivalent must be 
implemented 
1  
Align quality policy to include aspects 
specific to food contact including aspects of 
internal audit. 
1  
Management backing for GMP systems. 1  
Appoint a person to be responsible for GMP 
implementation and maintenance. 
2 
Applies generally to larger 
operations although it is always 
advisable to have a named 
individual with nominal 
responsibility. 
New and existing personnel and contractors 
should be trained on GMP requirements and 
hygiene aspects specific to the food contact 
product. 
1 
Needs apply only to personnel 
working in areas where the food 
contact product could be affected.  
Informal briefings may suffice in 
circumstances where the risk is 
low. 
Training records should be maintained for 
all personnel that have been trained. 
1 
Could be a full training course 
record or a tick in a box depending 
on the circumstances. 
Perform a risk analysis and review once per 
year. 
1  
Revise risk analysis. 3 Only needed when any major 
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product  or process change takes 
place  
Specifications   
Review and implement changes in 
regulations, customer demands and other 
rules and procedures related to food contact 
materials. Communicate changes within the 
organization. 
1 
It is not necessary to perform the 
review of regulations within the 
organization. Instead, the 
knowledge could be acquired from 
elsewhere 
The final product should be tested according 
to Bfr Recommendation 36 or the Industry 
Guideline or other relevant regulatory 
measures. The mill should have a 
documented procedure which defines which 
tests to carry out and the testing protocols to 
be used. 
1  
The quality assurance system must contain 
guidelines for the determination of testing 
frequency for requirements contained in the 
regulatory measures. 
2  
In cases where a decision has been taken to 
perform no tests on a particular requirement 
specified in the measures, documented 
reasoning must be prepared. 
1  
Procedures for ensuring the accuracy of 
substance input using dosing equipment 
should be in place to ensure correct addition 
of chemicals with a compositional limit. 
3  
Quality Control   
There must be a system in place to monitor 
and record the implementation and 
1  
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achievement of GMP. The system must also 
identify measures to correct any failure to 
achieve GMP and monitor the effectiveness 
of those measures. The system should cover 
also cases of non conformity with 
regulatory, internal and customer 
specifications. 
Document the food applications for which 
the end product can be used based on 
customer information or, in its absence, 
product knowledge. Document the effect 
which those applications might have on the 
selection of raw materials. 
3 
Ideally, the customer will provide 
details of end use but, if the 
customer is unable or unwilling to 
provide such information, then the 
customer must be told that he has 
responsibility for safe use of the 
product. 
Raw Materials   
All raw materials and additives used in the 
production of the food contact material 
should be assessed to ensure accordance 
with current regulatory requirements. 
1 
Suppliers must provide 
documentation showing conformity 
with current regulations.  In cases 
where suppliers 
introduce new raw materials or 
additives to their products, where 
new suppliers are used or the 
regulations change, a fresh 
declaration of conformity must be 
sought. 
Keep records of all raw material deliveries 
so that conformity with regulatory 
requirements can be checked. 
1  
Recipes of the end product, showing raw 
materials and additives used along the 
2 
Without this check, the operation 
will be unable to allocate 
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process, must be compiled and retained. responsibility to a supplier in the 
case of defective raw material. 
Suppliers of recovered paper must supply 
documented evidence of conformity with 
the Responsible Sourcing Guidelines and 
the requirement for that conformity should 
be included in the contractual arrangements 
with those recovered paper suppliers. 
1  
The operation of paper mills using 
recovered paper must be adapted, if 
necessary, to conform to the Responsible 
Sourcing Guidelines. 
1  
Personal Hygiene   
Personnel must wash their hands after using 
the toilet and any other activity that caused 
dirty hands. 
3  
Clean working clothes and working shoes 
should be worn in the production and 
storage areas. 
3  
It is not permitted to wear any loose items 
such as jewellery, watches, etc. 
3  
Open wounds shall be covered with plasters 
having a deep, distinctive color. If any 
subsequent processing equipment has a 
metal detection system, the plasters should 
be metal detectable. 
3  
Personal belongings must not be taken into 
the production and storage areas. 
3  
Working clothes should be selected with the 
safety of both the employee and the product 
3  
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in mind. There should be rules in place for 
effecting the upkeep and repair of these 
clothes. 
Employees suffering from injuries and/or 
diseases likely to be transmitted to the food 
contact material must be excluded from the 
workplace. 
3  
Eating, drinking, sweets, chewing gum and 
smoking are allowed in designed areas only. 
3  
Rules shall be in place to ensure that visitors 
to the workplace wear appropriate clothing 
and remove jewellery and other loose items. 
Personnel accompanying visitors must have 
sufficient knowledge to pass on to them the 
special requirements needed when working 
close to a food contact product. 
3  
Premises and Equipment   
All premises used by personnel working on 
food contact material, must be kept clean 
and tidy in accordance with a pre-
determined schedule. 
1 
Applies only to the production 
areas. 
Buildings, machinery, conveyors, transport 
devices, etc. must be cleaned regularly using 
a pre-determined schedule. Cleaning 
equipment and materials should be selected, 
used and stored in such a way that the food 
contact product is not adversely affected. 
1 
Applies only to the production 
areas. 
Regular maintenance and inspection of 
facilities for hygiene purpose should form 
part of the quality management system. 
2 
Applies only to the production 
areas.  
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Engineering, maintenance and technical 
equipment together with any necessary 
temporary construction arrangements used 
for specific, short-term tasks close to the 
production facilities should be removed 
when the task is complete. Delays to this 
procedure must be referred to the person 
having responsibility for the GMP system. 
1 
Applies only to the production 
areas.  
Lightning equipment, glass and plastic 
materials must be shatterproof. 
1 
Applies only in areas where the 
risk analysis has shown that debris 
from breakages could enter the 
food contact product. 
All unnecessary glass and clear hard plastic 
should be removed from production and 
storage areas. 
1 
Applies only in areas where the 
risk analysis has shown that debris 
from breakages could enter the 
food contact product. 
Hand knives used in production areas must 
be of an authorized type. Snap-off blades 
are specifically prohibited. 
1 
Applies only in areas where the 
risk analysis has shown that debris 
from blades could enter the food 
contact product.  
In the event of the breakage of glass, 
plastics, knives, etc. in the area of the food 
contact product, a procedure must be 
implemented to ensure that the food contact 
product being produced at the time of the 
incident is free of such debris. 
1 
This will require liaison between 
affected departments in the paper 
mill and may require the affected 
product to be destroyed. 
A documented pest control system must be 
in place.  Execution of the system must be 
by specialist contractors or personnel 
trained in the necessary techniques.  There 
1 
The system must ensure that pests 
cannot adversely affect the food 
contact product or its raw 
materials. 
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should be a recognized system for taking 
action where evidence of pests is noted.
  
Wherever possible, doors and windows 
should be screened or closed to prevent pest 
ingress. 
1 
Does not apply to areas not used 
for production or product storage. 
Documentation   
Arrangements must be implemented to 
produce documentation for external 
inspection. 
1 
Continuous production of 
documentation is not needed and 
reports could, for example, be 
produced in retrospect from 
computer records. Examples of the 
required information 
are:  
 Results of risk analysis 
 Changes in supply and 
suppliers 
 Raw material usage 
 Manufacturing and 
traceability documentation 
(mainly machine logs 
 Occurrences of deviation 
from specification and 
corrective measures 
(including changes required 
by new requirements from 
legislators).
 Results of testing within 
quality control systems and 
all ISO 9001 (or equivalent) 
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documentation. 
Miscellaneous   
All vehicles used for transporting finished 
paper should be suitable for the purpose, 
well maintained and in a state of good 
hygiene.  Ongoing contractual arrangements 
with transport companies shall include 
requirements for hygiene and cleaning. 
There should be a procedure in place for 
checking transport of finished products for 
cleanliness and water tightness. 
2  
All external warehouses should be suitable 
for the purpose, have appropriate 
atmospheric conditions, be well maintained 
and in a clean state.  Contractual 
arrangements with the supplier of 
warehousing facilities shall include 
requirements for hygiene and cleaning. 
2  
 
Key to ―Need‖ Column: 
1 = fundamental part of GMP, must be implemented in all cases 
2 = strongly advised 
3 = needed only if called for by the risk assessment 
 
 
2.3      MONOCLONAL ANTIBODIES (MABs) 
 
Monoclonal antibodies (MAb‘s) are used in diagnostic tests as well as for therapeutic purposes. 
World demand for currently approved MAb‘s is on the order of a few kilograms per year.  However, 
new therapeutic MAb‘s are under development that requires doses of several hundred milligrams to 
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a gram over the course of therapy (Seaver, 1997). The world demand for such products will exceed 
100 kg per year.  Current production choices for MAb‘s are limited to three well-established 
systems: ascites, stirred tank bioreactors (STR), and hollow-fiber bioreactors.  Alternative 
technologies under development include transgenic animals and genetically altered plants 
(DeYoung, 1996). Currently, stirred tank bioreactors tend to be favored for production of MAb‘s in 
kilogram quantities. They are operated under batch, fed-batch, or perfusion mode. 
Monoclonal antibodies (MABs) are widely used in pharmaceutical field as a main 
component for treatment of many kinds of diseases. Since the uses of MABs become larger 
day by day, countries are now competing to become MABs producer. Here are some 
examples on the uses of MABs: 
 
1. Murine monoclonal antibodies (MoAb) potentially can be used in the 
radioimmunodetection and radioimmunotherapy of cancer (Chaudhuri T.R, 1994). 
 
2. Antibodies are used in several diagnostic tests to detect small amounts of drugs, 
toxins or hormones, e.g. monoclonal antibodies to human chorionic gonadotropin 
(HCG) are used in pregnancy test kits (Biotech, 1989). Another diagnostic uses of 
antibodies is the diagnosis of AIDS by the ELISA test. 
 
3. Antibodies are used in the radioimmunodetection and radioimmunotherapy of 
cancer, and some new methods can even target only the cell membranes of 
cancerous cells (Chaudhari et al, 1994). A new cancer drug based on monoclonal 
antibody technology is Ritoxin, approved by the FDA in November 1997 (Orrs, 
1997). 
 
4. Monoclonal antibodies can be used to treat viral diseases, traditionally considered 
"untreatable". In fact, there is some evidence to suggest that antibodies may lead to 
a cure for AIDS (P/S/L, 1997). 
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5. Monoclonal antibodies can be used to classify strains of a single pathogen, e.g. 
Neisseria gonorrhoeae can be typed using monoclonal antibodies (Wang et al, 
1977). 
 
6. Researchers use monoclonal antibodies to identify and to trace specific cells or 
molecules in an organism, e.g. developmental biologists at tyhe University of 
Oregon use monoclonal antibodies to find out which proteins are responsible for 
cell differentiation in the respiratory system (Fratella, 1998). 
 
7. OKT3, an antibody to the T3 antigen of T cells, is used to alleviate the problem of 
organ rejection in patients who have had organ transplants (Transweb, 1996). 
 
According to Kelly B, 2009. The field of bioprocess development for mAb production finds 
itself at a crossroads resulting from significant changes in multiple factors impinging on 
process design targets. The combination of excess production capacity and increasing cell 
culture titers enables simple strategies and platform processes to meet market demand for 
nearly all mAbs in the development pipeline, and enjoy sufficiently low production costs 
resulting in drug substance Cost of Goods, COGs not being a key process design driver. 
This could lead to a frameshift in process development strategies, and a slowing of the 
relentless march to develop processes with higher and higher titers. The new paradigm 
would suggest that if acceptable standards of productivity and COGs are met, then one 
should not make process design decisions based on perceptions of capacity limits, 
purification bottlenecks, or COGs pressures for anything but the most unusual situations 
(noting that clinical production drivers could be different). 
 
In this case, the objectives of process development groups would shift from a focus on 
invention and innovation for new technologies to optimization and maturation of current 
production technology. The maturation phase should allow for continued refinement and 
improvements in manufacturing technology and COGs reductions, but will be more 
evolutionary than revolutionary. This may reflect a natural progression for process 
technologies driven by the introduction of new classes of products. In one theory of the link 
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between product and process innovation, process innovation lags behind product 
innovation, but eventually peaks and declines as the product class becomes a well-
established market.  The decreasing rate or need for process innovation could reflect 
maturing production technology, maximization of returns on the capital sunk into existing 
facilities, diminishing returns of new technology, and other factors. 
This situation would allow companies to avoid risky process development designs that 
could have challenges in scale-up, technology transfer or reliance on a single raw material 
suppler. Novel production technology should be carefully evaluated and implemented only 
if it is clearly enabling and concrete drivers are identified. Novelty for novelty‘s sake is no 
reason to stray from an acceptable processing platform that enables portability among the 
many facilities that share a common design basis, and offers attractive economies of scale. 
A focus on controlling product quality and process consistency at all production scales and 
facilities would trump minor improvements in titer improvements or COGs reduction. 
 
 Development objectives should shift to a focus on understanding the process fundamentals 
of the current platform. There are many areas of research relevant to bioprocess 
technologies associated with antibody expression and purification that should continue to 
drive investment in areas of cell biology, biochemical engineering, protein chemistry and 
stability. Even today‘s state of certain critical quality attributes, such as stability and levels 
of mAb expression, minimization of sequence variants, etc. For production cultures, 
modeling and manipulation of cellular metabolism to control accumulation of waste 
products such as lactate, understanding recent observations of disulfide bond reduction in 
high-titer mAb processes, and refining scale-down process models would all be valuable 
areas of research. Considering purification processes, the complexities of cell harvest and 
depth filtration should be studied, measurement of product binding isotherms and binding 
kinetics would enable chromatographic modeling of product and impurity separations, virus 
retaining filter fouling behavior should be better understood, and characterization and 
control of both soluble and insoluble product aggregates offer fertile grounds for 
investigation. For all unit operations in the current platform, these investments in 
fundamental understanding will expand the knowledge space for the manufacturing 
